is this based on MoA of ANTH's drug theoretically being superior in some way
yes
but early, it could be better, or just as good. or could have a safety issue. But I would prefer to have all my eggs in that basket than have them spend money on an acs trial that I think has a 95 percent chance of failing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.